y90 monoclonal antibody hu3s193
mAbexperimentalADC
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2000 (NCT00006046)
Timeline
Indications
Mechanism of action
- Lewis Y antigenImmunity, passive
Lewis Y antigen immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- hu3s193 monoclonal antibody
- monoclonal antibody hu3s193
- monoclonal antibody hu3s193
- y90 monoclonal antibody hu3s193
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01137071 | Phase 2 | Apr 1, 2011 | Recepta Biopharma |
| NCT00084799 | Phase 1 | Feb 1, 2004 | Cornell University, Ludwig Institute for Cancer Research, National Cancer Institute (NCI) |
| NCT00072410 | Phase 1 | Jun 1, 2003 | Cornell University, National Cancer Institute (NCI) |
| NCT00006046 | Phase 1 | Jan 1, 2000 | Cornell University, National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 3 | 2 | 1 | 2000 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 1 | 2000 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Recepta Biopharma | For profit | 1 | 1 | 1 | 2011 |
4 organizations
Page 1 / 1